Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Safety Information

I1782

Sigma-Aldrich

Inosine Monophosphate Dehydrogenase Type II human

recombinant, expressed in E. coli

Synonym(s):

IMP:NAD oxidoreductase, IMPDH II

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Enzyme Commission number:
1.1.1.205 (BRENDA, IUBMB)
MDL number:
MFCD04975063
UNSPSC Code:
12352204
NACRES:
NA.54

recombinant

expressed in E. coli

Quality Level

200

form

solution

specific activity

≥0.05 units/mg protein

mol wt

~55 kDa

packaging

vial of ≥0.002 unit

UniProt accession no.

P12268

relevant disease(s)

cancer

shipped in

dry ice

storage temp.

−70°C

Gene Information

human ... IMPDH2(3615)

Related Categories

General description

Inosine Monophosphate Dehydrogenase Type II (IMPDH2) is a ubiquitously expressed dominant isoform during developmental stages. IMPDH2 gene is mapped to human chromosome 3p21.31.

Application

Inosine Monophosphate Dehydrogenase Type II human has been used to test the inhibitory effect on vacor adenine dinucleotide (VAD) on its dehydrogenase activity.

Biochem/physiol Actions

Inosine Monophosphate Dehydrogenase Type II (IMPDH2) binds to adenosine triphosphate (ATP) and guanosine triphosphate (GTP). It catalyzes the formation of xanthosine monophosphate from inosine monophosphate in the presence of nicotinamide adenine dinucleotide (NAD). IMPDH2 elevated levels in tumors are correlated to its rate-limiting activity in guanosine monophosphate (GMP) synthesis. High levels of IMPDH2 is implicated in glioblastoma (GBM). It is regarded as a potential therapeutic target against tumors, antiviral, and immunosuppression-related pathologies.
Type II is the predominant IMPDH isoform and is specifically linked to a wide range of cancers and lymphocyte proliferation.

Unit Definition

One unit will produce 1.0 μ mole of XMP from IMP with corresponding reduction of β-NAD per minute at pH 8.0 at 25 °C.

Physical form

Solution in 20 mM Tris-HCl, pH 8.0, containing 0.5 mM EDTA and 1 mM DTT.

related product

Product No.
Description
Pricing

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

I1782-125UL:
I1782-BULK:
I1782-VAR:
I1782-1VL:

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Magdalena Makowska-Grzyska et al.
Biochemistry, 51(31), 6148-6163 (2012-07-14)
Inosine 5'-monophosphate dehydrogenase (IMPDH) catalyzes the first unique step of the GMP branch of the purine nucleotide biosynthetic pathway. This enzyme is found in organisms of all three kingdoms. IMPDH inhibitors have broad clinical applications in cancer treatment, as antiviral
Flavia Schmidt et al.
Archives of toxicology, 87(2), 361-370 (2012-08-24)
Mycophenolic acid (MPA) is an immunosuppressive agent that acts as a selective, non-reversible inhibitor of the enzyme inosine-5'-monophosphate dehydrogenase (IMPDH). Malformations have been described in children after maternal exposure to mycophenolate. However, the causal link is unclear in most cases
Veeraraghavan Usha et al.
PloS one, 7(3), e33886-e33886 (2012-04-06)
Tuberculosis (TB) remains a leading cause of mortality worldwide. With the emergence of multidrug resistant TB, extensively drug resistant TB and HIV-associated TB it is imperative that new drug targets be identified. The potential of Mycobacterium tuberculosis inosine monophosphate dehydrogenase
Magdalena Malachowska-Ugarte et al.
European journal of medicinal chemistry, 54, 197-201 (2012-05-25)
Hybrid pharmacophore anti-proliferative compounds, comprised of mycophenolic acid (MPA) and 1-nitroacridine/4-nitroacridone derivative have been synthesized and evaluated as inhibitors of five different leukemia cell lines (Jurkat, Molt-4, HL-60, CCRF-CEM, L1210) and human peripheral blood mononuclear cells from healthy donors. These
Chetan P Shah et al.
Journal of enzyme inhibition and medicinal chemistry, 33(1), 972-977 (2018-05-25)
Human inosine 5'-monophosphate dehydrogenase 2 (hIMPDH2), being an age-old target, has attracted attention recently for anticancer drug development. Mycophenolic acid (MPA), a well-known immunosuppressant drug, was used a lead structure to design and develop modestly potent and selective analogues. The
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service